These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27287718)

  • 81. Cancer stem cells and evolving novel therapies: a paradigm shift.
    Naveen SV; Kalaivani K
    Stem Cell Investig; 2018; 5():4. PubMed ID: 29430460
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Therapeutic Versatility of Resveratrol Derivatives.
    Nawaz W; Zhou Z; Deng S; Ma X; Ma X; Li C; Shu X
    Nutrients; 2017 Oct; 9(11):. PubMed ID: 29109374
    [TBL] [Abstract][Full Text] [Related]  

  • 83. APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases.
    Nguyen CB; Houchen CW; Ali N
    Exp Biol Med (Maywood); 2017 Feb; 242(3):242-249. PubMed ID: 27694285
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Viral hepatitis and liver cancer: the case of hepatitis C.
    Levrero M
    Oncogene; 2006 Jun; 25(27):3834-47. PubMed ID: 16799625
    [TBL] [Abstract][Full Text] [Related]  

  • 85. (Z)-3,5,4'-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression.
    Nguyen CB; Kotturi H; Waris G; Mohammed A; Chandrakesan P; May R; Sureban S; Weygant N; Qu D; Rao CV; Dhanasekaran DN; Bronze MS; Houchen CW; Ali N
    Cancer Res; 2016 Aug; 76(16):4887-96. PubMed ID: 27287718
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Fluvastatin interferes with hepatitis C virus replication via microtubule bundling and a doublecortin-like kinase-mediated mechanism.
    Ali N; Allam H; Bader T; May R; Basalingappa KM; Berry WL; Chandrakesan P; Qu D; Weygant N; Bronze MS; Umar S; Janknecht R; Sureban SM; Huycke M; Houchen CW
    PLoS One; 2013; 8(11):e80304. PubMed ID: 24260365
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action.
    Scherzberg MC; Kiehl A; Zivkovic A; Stark H; Stein J; Fürst R; Steinhilber D; Ulrich-Rückert S
    Toxicol Appl Pharmacol; 2015 Aug; 287(1):67-76. PubMed ID: 26044878
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
    Kwon YC; Bose SK; Steele R; Meyer K; Di Bisceglie AM; Ray RB; Ray R
    J Virol; 2015 Nov; 89(22):11549-56. PubMed ID: 26355082
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
    Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
    Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.
    Ali N; Chandrakesan P; Nguyen CB; Husain S; Gillaspy AF; Huycke M; Berry WL; May R; Qu D; Weygant N; Sureban SM; Bronze MS; Dhanasekaran DN; Houchen CW
    Oncotarget; 2015 Aug; 6(24):20327-44. PubMed ID: 25948779
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cancer stem cell targeting: are we there yet?
    Jung Y; Kim WY
    Arch Pharm Res; 2015 Mar; 38(3):414-22. PubMed ID: 25666873
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Mouse models of liver cancer.
    Caviglia JM; Schwabe RF
    Methods Mol Biol; 2015; 1267():165-83. PubMed ID: 25636469
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Resveratrol supplementation: Where are we now and where should we go?
    Novelle MG; Wahl D; Diéguez C; Bernier M; de Cabo R
    Ageing Res Rev; 2015 May; 21():1-15. PubMed ID: 25625901
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.
    Bertino G; Demma S; Ardiri A; Proiti M; Gruttadauria S; Toro A; Malaguarnera G; Bertino N; Malaguarnera M; Malaguarnera M; Di Carlo I
    Biomed Res Int; 2014; 2014():203693. PubMed ID: 25089265
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Cancer stem cells converted from pluripotent stem cells and the cancerous niche.
    Kasai T; Chen L; Mizutani A; Kudoh T; Murakami H; Fu L; Seno M
    J Stem Cells Regen Med; 2014; 10(1):2-7. PubMed ID: 25075155
    [TBL] [Abstract][Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.